tetano
Editor, Senior Moderator
Future Oncol. 2020 May 14. doi: 10.2217/fon-2020-0369. [Epub ahead of print]
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Stroppa EM[SUP]1[/SUP], Toscani I[SUP]1[/SUP], Citterio C[SUP]1[/SUP], Anselmi E[SUP]1[/SUP], Zaffignani E[SUP]1[/SUP], Codeluppi M[SUP]2[/SUP], Cavanna L[SUP]1[/SUP].
Author information
Abstract
Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: Twenty-five cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: Twenty patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.
KEYWORDS:
cancer patients and COVID-19; cobicistat; darunavir; hydroxychloroquine; infection and cancer; lopinavir; oncology and coronavirus; ritonavir
PMID:32403946DOI:10.2217/fon-2020-0369
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Stroppa EM[SUP]1[/SUP], Toscani I[SUP]1[/SUP], Citterio C[SUP]1[/SUP], Anselmi E[SUP]1[/SUP], Zaffignani E[SUP]1[/SUP], Codeluppi M[SUP]2[/SUP], Cavanna L[SUP]1[/SUP].
Author information
Abstract
Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: Twenty-five cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: Twenty patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.
KEYWORDS:
cancer patients and COVID-19; cobicistat; darunavir; hydroxychloroquine; infection and cancer; lopinavir; oncology and coronavirus; ritonavir
PMID:32403946DOI:10.2217/fon-2020-0369